Publications by authors named "I Ghobrial"
Early therapeutic intervention in high-risk smoldering multiple myeloma (HR-SMM) has shown benefits, however, no studies have assessed whether biochemical progression or response depth predicts long-term outcomes. The single-arm I-PRISM phase II trial (NCT02916771) evaluated ixazomib, lenalidomide, and dexamethasone in 55 patients with HR-SMM. The primary endpoint, median progression-free survival (PFS), was not reached (NR) (95% CI: 57.
View Article and Find Full Text PDFDetection of light chain (LC) monoclonal gammopathies (MG) traditionally relies on serum free LC (FLC) κ, λ, and their ratio (κ/λ) reference ranges based on a mostly White population. We investigated FLC values in a racially diverse population by screening 10,035 individuals for heavy chain MG, identifying 9,028 negative cases whose FLC were measured. Participants included 4,149 from the PROMISE Study (US, n=2,383; South Africa, n=1,766) and 4,879 from the Mass General Brigham Biobank, with 44% self-identifying as Black.
View Article and Find Full Text PDFArticle Synopsis
- - Multiple myeloma is a type of cancer that affects plasma cells and develops over many years, becoming more complex with various genetic changes and an immune-suppressing environment.
- - Advanced stages of the disease exhibit mechanisms that help tumors evade treatment, particularly against T cell-based therapies like bispecific antibodies and CAR-T cells.
- - Researchers are conducting numerous clinical trials to explore the effectiveness and safety of these therapies for new and high-risk cases of multiple myeloma and are also looking into early treatment options to prevent disease progression.